Cargando…
Optimal use of lenvatinib in the treatment of advanced thyroid cancer
The development of orally active, multitargeted kinase inhibitors (MKIs) represents a significant advance in the treatment of progressive, metastatic thyroid cancer. Lenvatinib, an MKI targeting vascular endothelial growth factor receptor, fibroblast growth factor receptor, platelet-derived growth f...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6460646/ https://www.ncbi.nlm.nih.gov/pubmed/31093354 http://dx.doi.org/10.1186/s41199-017-0026-0 |
_version_ | 1783410359419273216 |
---|---|
author | Takahashi, Shunji Kiyota, Naomi Tahara, Makoto |
author_facet | Takahashi, Shunji Kiyota, Naomi Tahara, Makoto |
author_sort | Takahashi, Shunji |
collection | PubMed |
description | The development of orally active, multitargeted kinase inhibitors (MKIs) represents a significant advance in the treatment of progressive, metastatic thyroid cancer. Lenvatinib, an MKI targeting vascular endothelial growth factor receptor, fibroblast growth factor receptor, platelet-derived growth factor receptor, c-Kit, and RET, has shown efficacy in stabilizing previously progressive disease, with emerging evidence of a possible benefit in terms of overall survival. However, lenvatinib is associated with a side-effect profile similar to those of other MKIs that might affect the outcome of therapy. The aim of this review is to summarize the clinical efficacy and safety of MKIs in the treatment of advanced thyroid cancer in pivotal phase III trials. Common adverse events that may occur during lenvatinib therapy and their management are discussed, including conditions in which its administration should be temporarily withdrawn and resumed pending resolution of adverse events. We focus on data from a subanalysis of Japanese patients in the SELECT trial and in a post-marketing study in Japan. We suggest that lenvatinib is a valuable treatment option for advanced differentiated thyroid cancer. Monitoring and careful management of adverse events including supportive care are required to ensure continuation of therapy. |
format | Online Article Text |
id | pubmed-6460646 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-64606462019-05-15 Optimal use of lenvatinib in the treatment of advanced thyroid cancer Takahashi, Shunji Kiyota, Naomi Tahara, Makoto Cancers Head Neck Review The development of orally active, multitargeted kinase inhibitors (MKIs) represents a significant advance in the treatment of progressive, metastatic thyroid cancer. Lenvatinib, an MKI targeting vascular endothelial growth factor receptor, fibroblast growth factor receptor, platelet-derived growth factor receptor, c-Kit, and RET, has shown efficacy in stabilizing previously progressive disease, with emerging evidence of a possible benefit in terms of overall survival. However, lenvatinib is associated with a side-effect profile similar to those of other MKIs that might affect the outcome of therapy. The aim of this review is to summarize the clinical efficacy and safety of MKIs in the treatment of advanced thyroid cancer in pivotal phase III trials. Common adverse events that may occur during lenvatinib therapy and their management are discussed, including conditions in which its administration should be temporarily withdrawn and resumed pending resolution of adverse events. We focus on data from a subanalysis of Japanese patients in the SELECT trial and in a post-marketing study in Japan. We suggest that lenvatinib is a valuable treatment option for advanced differentiated thyroid cancer. Monitoring and careful management of adverse events including supportive care are required to ensure continuation of therapy. BioMed Central 2017-10-24 /pmc/articles/PMC6460646/ /pubmed/31093354 http://dx.doi.org/10.1186/s41199-017-0026-0 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Takahashi, Shunji Kiyota, Naomi Tahara, Makoto Optimal use of lenvatinib in the treatment of advanced thyroid cancer |
title | Optimal use of lenvatinib in the treatment of advanced thyroid cancer |
title_full | Optimal use of lenvatinib in the treatment of advanced thyroid cancer |
title_fullStr | Optimal use of lenvatinib in the treatment of advanced thyroid cancer |
title_full_unstemmed | Optimal use of lenvatinib in the treatment of advanced thyroid cancer |
title_short | Optimal use of lenvatinib in the treatment of advanced thyroid cancer |
title_sort | optimal use of lenvatinib in the treatment of advanced thyroid cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6460646/ https://www.ncbi.nlm.nih.gov/pubmed/31093354 http://dx.doi.org/10.1186/s41199-017-0026-0 |
work_keys_str_mv | AT takahashishunji optimaluseoflenvatinibinthetreatmentofadvancedthyroidcancer AT kiyotanaomi optimaluseoflenvatinibinthetreatmentofadvancedthyroidcancer AT taharamakoto optimaluseoflenvatinibinthetreatmentofadvancedthyroidcancer |